William Blair Issues Positive Outlook for IONS Earnings

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) – Analysts at William Blair upped their Q1 2025 earnings estimates for Ionis Pharmaceuticals in a research report issued on Monday, April 14th. William Blair analyst M. Minter now anticipates that the company will post earnings of ($1.23) per share for the quarter, up from their prior estimate of ($1.25). William Blair currently has a “Outperform” rating on the stock. The consensus estimate for Ionis Pharmaceuticals’ current full-year earnings is ($3.50) per share. William Blair also issued estimates for Ionis Pharmaceuticals’ Q2 2025 earnings at ($1.02) EPS, Q3 2025 earnings at ($0.83) EPS, Q4 2025 earnings at ($0.77) EPS, FY2025 earnings at ($3.84) EPS and FY2026 earnings at ($2.11) EPS.

Other equities analysts have also issued reports about the company. Needham & Company LLC reaffirmed a “buy” rating and issued a $60.00 target price on shares of Ionis Pharmaceuticals in a research report on Tuesday. Redburn Atlantic started coverage on shares of Ionis Pharmaceuticals in a research note on Monday, March 31st. They set a “neutral” rating and a $39.00 price objective on the stock. Citigroup dropped their target price on shares of Ionis Pharmaceuticals from $67.00 to $64.00 and set a “buy” rating for the company in a research report on Thursday, February 20th. StockNews.com upgraded shares of Ionis Pharmaceuticals to a “sell” rating in a research note on Tuesday, March 18th. Finally, Guggenheim reiterated a “buy” rating on shares of Ionis Pharmaceuticals in a research note on Thursday, April 3rd. Two equities research analysts have rated the stock with a sell rating, six have given a hold rating, eleven have issued a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $56.72.

Ionis Pharmaceuticals Trading Up 0.2 %

NASDAQ:IONS opened at $28.40 on Thursday. Ionis Pharmaceuticals has a one year low of $23.95 and a one year high of $52.34. The business’s 50-day simple moving average is $30.93 and its 200 day simple moving average is $34.31. The company has a debt-to-equity ratio of 2.12, a quick ratio of 8.82 and a current ratio of 8.47. The stock has a market cap of $4.51 billion, a price-to-earnings ratio of -9.34 and a beta of 0.29.

Ionis Pharmaceuticals (NASDAQ:IONS) last issued its quarterly earnings data on Wednesday, February 19th. The company reported ($0.66) EPS for the quarter, topping analysts’ consensus estimates of ($1.12) by $0.46. The firm had revenue of $227.00 million for the quarter, compared to analyst estimates of $140.97 million. Ionis Pharmaceuticals had a negative net margin of 64.25% and a negative return on equity of 100.05%. The firm’s revenue was down 30.2% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.12 EPS.

Insider Activity at Ionis Pharmaceuticals

In other news, CEO Brett P. Monia sold 13,242 shares of the stock in a transaction on Friday, January 31st. The stock was sold at an average price of $32.45, for a total value of $429,702.90. Following the transaction, the chief executive officer now owns 219,526 shares of the company’s stock, valued at $7,123,618.70. This represents a 5.69 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, EVP Patrick R. O’neil sold 1,207 shares of Ionis Pharmaceuticals stock in a transaction on Thursday, February 20th. The stock was sold at an average price of $32.35, for a total value of $39,046.45. Following the sale, the executive vice president now directly owns 56,245 shares of the company’s stock, valued at approximately $1,819,525.75. This trade represents a 2.10 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 63,167 shares of company stock worth $2,010,458 over the last 90 days. Insiders own 2.71% of the company’s stock.

Hedge Funds Weigh In On Ionis Pharmaceuticals

Several institutional investors have recently modified their holdings of IONS. Xponance Inc. grew its holdings in Ionis Pharmaceuticals by 1.7% during the fourth quarter. Xponance Inc. now owns 19,339 shares of the company’s stock valued at $676,000 after purchasing an additional 318 shares during the period. Amalgamated Bank grew its holdings in shares of Ionis Pharmaceuticals by 3.4% in the 4th quarter. Amalgamated Bank now owns 10,292 shares of the company’s stock valued at $360,000 after buying an additional 335 shares during the period. Vontobel Holding Ltd. increased its position in shares of Ionis Pharmaceuticals by 6.6% in the 4th quarter. Vontobel Holding Ltd. now owns 5,865 shares of the company’s stock valued at $205,000 after buying an additional 363 shares in the last quarter. Commonwealth Equity Services LLC increased its position in shares of Ionis Pharmaceuticals by 1.7% in the 4th quarter. Commonwealth Equity Services LLC now owns 21,826 shares of the company’s stock valued at $763,000 after buying an additional 373 shares in the last quarter. Finally, Treasurer of the State of North Carolina raised its stake in Ionis Pharmaceuticals by 0.6% during the 4th quarter. Treasurer of the State of North Carolina now owns 68,803 shares of the company’s stock worth $2,405,000 after buying an additional 440 shares during the period. 93.86% of the stock is currently owned by institutional investors and hedge funds.

About Ionis Pharmaceuticals

Ionis Pharmaceuticals, Inc discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy.